Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio trimmed its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 9.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 72,758 shares of the medical equipment provider's stock after selling 7,276 shares during the quarter. Public Employees Retirement System of Ohio's holdings in Zimmer Biomet were worth $7,685,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in ZBH. Neo Ivy Capital Management raised its holdings in Zimmer Biomet by 371.7% in the 4th quarter. Neo Ivy Capital Management now owns 6,528 shares of the medical equipment provider's stock valued at $689,000 after buying an additional 5,144 shares during the period. CSS LLC IL increased its position in shares of Zimmer Biomet by 28.0% during the fourth quarter. CSS LLC IL now owns 8,960 shares of the medical equipment provider's stock valued at $946,000 after acquiring an additional 1,960 shares during the last quarter. First Heartland Consultants Inc. acquired a new stake in shares of Zimmer Biomet during the fourth quarter valued at about $454,000. PharVision Advisers LLC acquired a new stake in shares of Zimmer Biomet during the fourth quarter valued at about $209,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Zimmer Biomet by 8.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,767,901 shares of the medical equipment provider's stock valued at $186,743,000 after acquiring an additional 140,531 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Needham & Company LLC reiterated a "hold" rating on shares of Zimmer Biomet in a research report on Friday, February 7th. JPMorgan Chase & Co. lowered their price objective on Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating for the company in a research report on Tuesday, May 6th. JMP Securities cut their price target on Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 7th. Royal Bank of Canada cut their price objective on shares of Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. Finally, Morgan Stanley cut their price objective on shares of Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $111.53.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares in the company, valued at $915,379.20. This trade represents a 14.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.70% of the stock is currently owned by company insiders.

Zimmer Biomet Price Performance

ZBH traded down $1.22 during trading on Friday, reaching $92.12. 3,505,131 shares of the stock were exchanged, compared to its average volume of 1,804,829. The company has a market capitalization of $18.23 billion, a price-to-earnings ratio of 20.70, a P/E/G ratio of 1.95 and a beta of 0.78. Zimmer Biomet Holdings, Inc. has a 1 year low of $89.92 and a 1 year high of $116.71. The business's 50 day moving average price is $100.36 and its two-hundred day moving average price is $104.92. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. The firm had revenue of $1.91 billion during the quarter, compared to the consensus estimate of $1.89 billion. During the same period in the previous year, the firm posted $1.94 EPS. The company's quarterly revenue was up 1.1% compared to the same quarter last year. As a group, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Thursday, June 26th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.04%. Zimmer Biomet's dividend payout ratio (DPR) is 21.24%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.